Key Takeaways

  • Elizabeth Holmes was acquitted of all criminal charges alleging fraud against patients, despite popular belief that Theranos was convicted for harming customers.
  • The federal government presented four individual patients at trial out of 12.5 million diagnostic tests administered by Theranos across an 18-month commercial run.
  • Billy Evans attributes missed Theranos revenue targets to Walgreens defaulting on signed commercial contracts after hostile media coverage hit, rather than fabricated pipeline models.
  • Medical diagnostics carry standard error rates ranging between 10% and 30%, which made isolated patient errors legally insufficient to prove criminal intent.

The 12.5 Million Test Reality Behind the Acquittals

The cultural narrative around Theranos suggests the company spent years issuing fake medical results to millions of unsuspecting customers. In federal court, the evidentiary standard told an entirely different story.

Holmes faced two distinct categories of wire fraud: defrauding investors and defrauding patients. The jury convicted her on four counts of investor fraud, leading to an 11-year prison sentence. They acquitted her on every single count involving patients.

Evans pointed directly to the sample size the prosecution managed to assemble after years of subpoena power and grand jury testimony.

“Liz ran about 12 and 1/2 million tests on patients at Theranos over an 18-month period. The government spent years investigating,” Evans said. “Of the 12 and 1/2 million tests that she ran, the government brought forward four patients that they accused her of defrauding with inaccurate results. She was acquitted of those counts. So, there was no evidence that was brought forward that was convincing to a jury that there was any fraud associated with patients.”

In clinical medicine, error rates exist across every commercial lab run by Quest or LabCorp. Evans noted that baseline testing accuracy often sits between 70% and 90% depending on the assay. Four bad test outcomes across 12.5 million patient interactions falls far below the normal baseline of false positives and false negatives found in routine pathology labs. The federal prosecutors could not prove a systemic scheme to distribute incorrect results to everyday consumers.

Commercial Contract Defaults vs. Fabricated Forecasts

The investor convictions rested heavily on financial models that Theranos circulated showing massive projected revenues. Critics cited those projections as deliberate fabrications invented out of whole cloth to raise venture rounds.

Evans challenged that characterization by pointing to the commercial structure behind the numbers. Theranos had executed formal distribution agreements with retail partners like Walgreens to open wellness centers inside retail pharmacy footprints across the United States.

“They had contractual obligations with Walgreens to pay them that amount of money,” Evans explained. “And then when bad press came out, then they defaulted on those obligations and then the business didn't fulfill those revenue obligations.”

There is a strict line between projecting revenue based on binding customer agreements and inventing hypothetical revenue to mislead limited partners. When partner counterparties back out of minimum commitment clauses due to reputational pressure, downstream earnings collapse. The jury decided that pitching those aggressive milestones to investors crossed the threshold into criminal misrepresentation, but the legal debate hinged on contractual execution rather than fictitious corporate phantom contracts.

The Legal Exposure That Actually Catches Founders

Founders often worry about operational glitches, product defects, and edge-case bugs sinking their company. The Theranos verdict proves that operational bugs, even when dealing with blood tests, rarely trigger criminal fraud convictions on their own.

What triggers federal prison time is the narrative sold to capital allocators to fund those operational experiments. The government failed to convince twelve jurors that running imperfect blood tests amounted to a patient conspiracy. They succeeded easily when showing private emails, pitch decks, and financial forecasts sent to wealthy investors that glossed over technical dependencies.

What to Do With This

Pull your current investor deck and audit every forward-looking revenue claim against your signed legal contracts tomorrow morning. If you have labeled a projected number as contractually guaranteed when the underlying agreement contains termination clauses, change of control carve-outs, or performance milestones, strip the word "guaranteed" immediately. Separate pipeline estimates from executed, non-contingent purchase orders in writing.